Claims for Patent: 5,976,879

Summary for Patent: 5,976,879

Title:	Antisense oligonucleotides which combat aberrant splicing and methods of using the same
Abstract:	A method of combatting aberrant splicing in a pre-mRNA molecule containing a mutation is disclosed. When present in the pre-mRNA, the mutation causes the pre-mRNA to splice incorrectly and produce an aberrant mRNA or mRNA fragment different from the mRNA ordinarily encoded by the pre-mRNA. The method comprises hybridizing an antisense oligonucleotide to the pre-mRNA molecule to create a duplex molecule under conditions which permit splicing. The antisense oligonucleotide is one which does not activate RNase H, and is selected to block a member of the aberrant set of splice elements created by the mutation so that the native intron is removed by splicing and the first mRNA molecule encoding a native protein is produced. Oligonucleotides useful for carrying out the method are also disclosed.
Inventor(s):	Kole; Ryszard (Chapel Hill, NC), Dominski; Zbigniew (Chapel Hill, NC)
Assignee:	The University of North Carolina at Chapel Hill (Chapel Hill, NC)
Application Number:	09/302,390
Patent Claims:	1. A method of combatting alternate splicing in a pre-mRNA molecule: wherein said pre-mRNA molecule contains a first set of splice elements defining a first intron which is removed by splicing to produce a first mRNA molecule encoding a first protein; and wherein said pre-mRNA further contains a second set of splice elements defining an alternate intron different from said first intron, which alternate intron is removed by splicing to produce an alternate second mRNA molecule different from said first mRNA molecule; said method comprising: hybridizing an antisense oligonucleotide to said pre-mRNA molecule to create a duplex molecule under conditions which permit splicing, wherein said antisense oligonucleotide does not activate RNase H; and wherein said oligonucleotide blocks a member of said alternate second set of splice elements; so that said first intron is removed by splicing and said first mRNA molecule encoding a protein is produced. 2. The method according to claim 1, wherein said antisense oligonucleotide blocks a mutated splice element. 3. The method according to claim 1, wherein said antisense oligonucleotide blocks a native splice element. 4. The method according to claim 1, wherein said antisense oligonucleotide blocks a cryptic splice element. 5. The method according to claim 1, wherein said antisense oligonucleotide blocks a 5' splice site. 6. The method according to claim 1, wherein said antisense oligonucleotide blocks a 3' splice site. 7. The method according to claim 1, wherein said antisense oligonucleotide blocks a branch point. 8. The method according to claim 1, wherein said hybridizing step is carried out in a cell, and wherein said first mRNA is translated into said native protein. 9. The method according to claim 1, wherein said native protein is .beta.-globin. 10. The method according to claim 1, wherein said native protein is human .beta.-globin. 11. The method according to claim 1, wherein said antisense oligonucleotide is from 8 to 50 nucleotides in length. 12. The method according to claim 1, wherein said antisense oligonucleotide contains a modified internucleotide bridging phosphate residue selected from the group consisting of methyl phosphonates, methyl phosphonothioates, phosphoromorpholidates, phosphoropiperazidates, and phosphoramidates. 13. The method according to claim 1, wherein said antisense oligonucleotide contains a nucleotide having a loweralkyl substituent at the 2' position thereof.

Details for Patent 5,976,879

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-01-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-01-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-01-26